Compound 711
Identifiers
- Canonical SMILES:
COc1c(C)ccc2O[C@@H](C3=C(N(C)c4ncnn4[C@H]3c3ccc(Br)cc3)c12)c1ccc(Br)cc1
- InChi:
InChI=1S/C27H22Br2N4O2/c1-15-4-13-20-21(25(15)34-3)24-22(26(35-20)17-7-11-19(29)12-8-17)23(16-5-9-18(28)10-6-16)33-27(32(24)2)30-14-31-33/h4-14,23,26H,1-3H3/t23-,26+/m0/s1
- InChiKey:
AKTJUOGFAHNFEA-JYFHCDHNSA-N
External links
44550015 |
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
MDM2-Like / P53 | 5.40 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 592.01 g/mol | |||
HBA | 6 | |||
HBD | 0 | |||
HBA + HBD | 6 | |||
AlogP | 6.86 | |||
TPSA | 52.41 | |||
RB | 3 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4317 | BMS-394136 | DB12067 | |
0.3713 | GDC-0927 | DB14934 | |
0.3498 | Rocaglamide | DB15495 | |
0.3489 | Desvancosaminyl vancomycin | DB04529 | |
0.3481 | Iclaprim | DB06358 | |
0.3481 | (S)-iclaprim | DB07938 | |
0.3481 | 5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine | DB08741 | |
0.3480 | Galicaftor | DB14894 | |
0.3466 | Didesmethylrocaglamide | DB15496 | |
0.3460 | Vancomycin | DB00512 | |
0.3430 | LY-2881835 | DB15046 | |
0.3411 | Balhimycin | DB04111 | |
0.3404 | (4aS,6R,8aS)-11-[8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium | DB02673 | |
0.3403 | 4-epi-vancosaminyl derivative of vancomycin | DB04431 | |
0.3372 | Cannabichromene | DB14735 |